Literature DB >> 28787396

Silencing Intersectin 1 Slows Orthotopic Neuroblastoma Growth in Mice.

Jamie Harris1, Erika Herrero-Garcia, Angela Russo, Andre Kajdacsy-Balla, John P O'Bryan, Bill Chiu.   

Abstract

Neuroblastoma accounts for 15% of all pediatric cancer deaths. Intersectin 1 (ITSN1), a scaffold protein involved in phosphoinositide 3-kinase (PI3K) signaling, regulates neuroblastoma cells independent of MYCN status. We hypothesize that by silencing ITSN1 in neuroblastoma cells, tumor growth will be decreased in an orthotopic mouse tumor model. SK-N-AS neuroblastoma cells transfected with empty vector (pSR), vectors expressing scrambled shRNA (pSCR), or shRNAs targeting ITSN1 (sh#1 and sh#2) were used to create orthotopic neuroblastoma tumors in mice. Volume was monitored weekly with ultrasound. End-point was tumor volume >1000 mm. Tumor cell lysates were analyzed with anti-ITSN1 antibody by Western blot. Orthotopic tumors were created in all cell lines. Twenty-five days post injection, pSR tumor size was 917.6±247.7 mm, pSCR was 1180±159.9 mm, sh#1 was 526.3±212.8 mm, and sh#2 was 589.2±74.91 mm. sh#1-tumors and sh#2-tumors were smaller than pSCR (P=0.02), no difference between sh#1 and sh#2. Survival was superior in sh#2-tumors (P=0.02), trended towards improved survival in sh#1-tumors (P=0.09), compared with pSCR-tumors, no difference in pSR tumors. Western blot showed decreased ITSN1 expression in sh#1 and sh#2 compared with pSR and pSCR. Silencing ITSN1 in neuroblastoma cells led to decreased tumor growth in an orthotopic mouse model. Orthotopic animal models can provide insight into the role of ITSN1 pathways in neuroblastoma tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28787396      PMCID: PMC5656511          DOI: 10.1097/MPH.0000000000000931

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  18 in total

1.  Intersectin, an adaptor protein involved in clathrin-mediated endocytosis, activates mitogenic signaling pathways.

Authors:  A Adams; J M Thorn; M Yamabhai; B K Kay; J P O'Bryan
Journal:  J Biol Chem       Date:  2000-09-01       Impact factor: 5.157

2.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

3.  Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK.

Authors:  Robert P Mohney; Margaret Das; Trever G Bivona; Richard Hanes; Anthony G Adams; Mark R Philips; John P O'Bryan
Journal:  J Biol Chem       Date:  2003-09-11       Impact factor: 5.157

4.  Intersectin regulates epidermal growth factor receptor endocytosis, ubiquitylation, and signaling.

Authors:  Negin P Martin; Robert P Mohney; Sara Dunn; Margaret Das; Erica Scappini; John P O'Bryan
Journal:  Mol Pharmacol       Date:  2006-08-16       Impact factor: 4.436

5.  Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity.

Authors:  S Urlinger; U Baron; M Thellmann; M T Hasan; H Bujard; W Hillen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

6.  Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma.

Authors:  Jun S Wei; Braden T Greer; Frank Westermann; Seth M Steinberg; Chang-Gue Son; Qing-Rong Chen; Craig C Whiteford; Sven Bilke; Alexei L Krasnoselsky; Nicola Cenacchi; Daniel Catchpoole; Frank Berthold; Manfred Schwab; Javed Khan
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

7.  Oncogenic mutations of ALK kinase in neuroblastoma.

Authors:  Yuyan Chen; Junko Takita; Young Lim Choi; Motohiro Kato; Miki Ohira; Masashi Sanada; Lili Wang; Manabu Soda; Akira Kikuchi; Takashi Igarashi; Akira Nakagawara; Yasuhide Hayashi; Hiroyuki Mano; Seishi Ogawa
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

8.  Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma.

Authors:  Louis Chesler; David D Goldenberg; Isha T Seales; Ronit Satchi-Fainaro; Matt Grimmer; Rodney Collins; Chris Struett; Kim N Nguyen; Grace Kim; Tarik Tihan; Yun Bao; Rolf A Brekken; Gabriele Bergers; Judah Folkman; William A Weiss
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

Review 9.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

10.  Intersectin 1 is required for neuroblastoma tumorigenesis.

Authors:  A Russo; J P O'Bryan
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

View more
  2 in total

1.  Sex differences in the proliferation of pulmonary artery endothelial cells: implications for plexiform arteriopathy.

Authors:  Shanshan Qin; Dan N Predescu; Monal Patel; Patrick Drazkowski; Balaji Ganesh; Sanda A Predescu
Journal:  J Cell Sci       Date:  2020-05-14       Impact factor: 5.285

Review 2.  Targeting Rac and Cdc42 GEFs in Metastatic Cancer.

Authors:  Maria Del Mar Maldonado; Julia Isabel Medina; Luis Velazquez; Suranganie Dharmawardhane
Journal:  Front Cell Dev Biol       Date:  2020-04-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.